Követés
Khaled Barakat
Khaled Barakat
University of Alberta
E-mail megerősítve itt: ualberta.ca - Kezdőlap
Cím
Hivatkozott rá
Hivatkozott rá
Év
Molecular dynamics-driven drug discovery: leaping forward with confidence
A Ganesan, ML Coote, K Barakat
Drug discovery today 22 (2), 249-269, 2017
3752017
Cardiac late sodium channel current is a molecular target for the sodium/glucose cotransporter 2 inhibitor empagliflozin
K Philippaert, S Kalyaanamoorthy, M Fatehi, W Long, S Soni, NJ Byrne, ...
Circulation 143 (22), 2188-2204, 2021
1752021
Discovery and characterization of the laulimalide-microtubule binding mode by mass shift perturbation mapping
MJ Bennett, K Barakat, JT Huzil, J Tuszynski, DC Schriemer
Chemistry & biology 17 (7), 725-734, 2010
1472010
Development of safe drugs: the hERG challenge
S Kalyaanamoorthy, KH Barakat
Medicinal research reviews 38 (2), 525-555, 2018
1382018
Comprehensive in vitro characterization of PD-L1 small molecule inhibitors
A Ganesan, M Ahmed, I Okoye, E Arutyunova, D Babu, WL Turnbull, ...
Scientific reports 9 (1), 12392, 2019
1332019
IL-28B is a key regulator of B-and T-cell vaccine responses against influenza
A Egli, DM Santer, D O'Shea, K Barakat, M Syedbasha, M Vollmer, ...
PLoS pathogens 10 (12), e1004556, 2014
1182014
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
IS Okoye, M Houghton, L Tyrrell, K Barakat, S Elahi
Frontiers in immunology 8, 1215, 2017
1122017
Computational predictions of volatile anesthetic interactions with the microtubule cytoskeleton: Implications for side effects of general anesthesia
TJA Craddock, M St. George, H Freedman, KH Barakat, S Damaraju, ...
PLoS One 7 (6), e37251, 2012
1122012
Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells
LP Jordheim, KH Barakat, L Heinrich-Balard, EL Matera, E Cros-Perrial, ...
Molecular pharmacology 84 (1), 12-24, 2013
1062013
Immunomodulatory function of interleukin 28B during primary infection with cytomegalovirus
A Egli, A Levin, DM Santer, M Joyce, D O'Shea, BS Thomas, LF Lisboa, ...
The Journal of infectious diseases 210 (5), 717-727, 2014
922014
Virtual screening and biological evaluation of inhibitors targeting the XPA-ERCC1 interaction
KH Barakat, LP Jordheim, R Perez-Pineiro, D Wishart, C Dumontet, ...
PLoS One 7 (12), e51329, 2012
812012
DNA polymerase beta (pol β) inhibitors: A comprehensive overview
KH Barakat, MM Gajewski, JA Tuszynski
Drug discovery today 17 (15-16), 913-920, 2012
812012
Ensemble-based virtual screening reveals dual-inhibitors for the p53–MDM2/MDMX interactions
K Barakat, J Mane, D Friesen, J Tuszynski
Journal of Molecular Graphics and Modelling 28 (6), 555-568, 2010
802010
Targeting B7‐1 in immunotherapy
R Chen, A Ganesan, I Okoye, E Arutyunova, S Elahi, MJ Lemieux, ...
Medicinal research reviews 40 (2), 654-682, 2020
582020
Human PD-1 binds differently to its human ligands: a comprehensive modeling study
C Viricel, M Ahmed, K Barakat
Journal of Molecular Graphics and Modelling 57, 131-142, 2015
572015
A refined model of the HCV NS5A protein bound to daclatasvir explains drug-resistant mutations and activity against divergent genotypes
KH Barakat, A Anwar-Mohamed, JA Tuszynski, MJ Robins, DL Tyrrell, ...
Journal of chemical information and modeling 55 (2), 362-373, 2015
552015
DNA repair inhibitors: the next major step to improve cancer therapy
K Barakat, M Gajewski, J a Tuszynski
Current topics in medicinal chemistry 12 (12), 1376-1390, 2012
542012
A human ether-á-go-go-related (hERG) ion channel atomistic model generated by long supercomputer molecular dynamics simulations and its use in predicting drug cardiotoxicity
A Anwar-Mohamed, KH Barakat, R Bhat, SY Noskov, DL Tyrrell, ...
Toxicology letters 230 (3), 382-392, 2014
532014
Effects of temperature on the p53-DNA binding interactions and their dynamical behavior: comparing the wild type to the R248Q mutant
K Barakat, BB Issack, M Stepanova, J Tuszynski
PloS one 6 (11), e27651, 2011
532011
Computer-aided drug design
PV Bharatam
Drug discovery and development: From targets and molecules to medicines, 137-210, 2021
522021
A rendszer jelenleg nem tudja elvégezni a műveletet. Próbálkozzon újra később.
Cikkek 1–20